All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Evidence to support the use of JAK inhibitors in the treatment of axial spondyloarthritis (axSpA) continues to grow based on new reports of positive data from phase 3 studies of filgotinib as well as

5h ago

Source

Twitter / XEvidence to support the use of JAK inhibitors in the treatment of axial spondyloarthritis (axSpA) continues to grow based on new reports of positive data from phase 3 studies of filgotinib as well asmdsc.pe
Snippet from the RSS feed
Evidence to support the use of JAK inhibitors in the treatment of axial spondyloarthritis (axSpA) continues to grow based on new reports of positive data from phase 3 studies of filgotinib as well as the investigational agents gecacitinib and ivarmacitinib and a phase 4 study of tofacitinib in early disease. If the studies’ findings hold up to further scrutiny, three more JAK inhibitors could soon be joining upadacitinib and tofacitinib as approved treatments for axSpA , it was reported during an oral abstract session at the European Alliance of Associations for Rheumatology (EULAR) 2026 Annual Meeting.

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.